PD 1-proIL-2v - Proviva Therapeutics
Alternative Names: PD-1-proIL-2vLatest Information Update: 19 Jul 2024
At a glance
- Originator Proviva Therapeutics
- Class Antineoplastics; Proteins; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 receptor agonists; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 04 Jul 2024 Proviva Therapeutics plans to initiate a phase I trial in early 2024
- 05 Apr 2024 Preclinical trials in Solid tumours in USA (Parenteral) prior to April 2024
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)